


# Bacterial Vaginosis Treatment | Market Size to Reach USD 1,450.4 Million by 2035, Report by IMARC Group

*The report also provides a detailed analysis of the current bacterial vaginosis marketed drugs and late-stage pipeline drugs, Advances in Treatment.*

BROOKLYN, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The [bacterial vaginosis market size reached a value of USD 806.4 Million](#) across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,450.4 Million by 2035, exhibiting a growth rate (CAGR) of 5.48% during 2025-2035.



Bacterial Vaginosis (BV) is the leading vaginal infection, arising when the delicate balance of bacteria in the vagina tips out of whack. Normally protective Lactobacillus is drowned out by larger numbers of unwanted germs, sparking the classic symptoms. These can include thin gray-white discharge, a fishy smell that often gets louder after intercourse, and mild itching or burning. BV touches a large share of women in their reproductive years; in the United States the estimate sits around 30 percent. Because it can appear even in women who are not sexually active, the need for reliable, easy-to-use treatments never fades.

Several factors are pushing the bacterial vaginosis market upward. First, the condition is common worldwide, and rising awareness among women and providers means more cases are recognized and treated, driving demand for care. Newer, sharper diagnostic tools catch BV earlier and with greater accuracy, enlarging the group of patients who seek help. At the same time, drug firms are pumping money into research, speeding the arrival of fresh therapies.

A clear trend is the urgent move toward non-antibiotic options. Standard antibiotic regimens often falter because the infection returns or bacteria resist the drugs; cure rates can dip to 50-80 percent, and women are left searching for something better. That gap creates a strong need for

longer-lasting answers. Pipeline candidates-XACIATO, SOLOSEC, LACTIN-V-show the shift toward products that help restore the vaginal microbiome instead of wiping it out. Growth in personalized medicine, which matches therapies to each patients profile, may lift success rates further and keep the market expanding.

Request a PDF Sample Report: <https://www.imarcgroup.com/bacterial-vaginosis-market/requestsample>

The report also provides a detailed analysis of the current bacterial vaginosis marketed drugs and late-stage pipeline drugs.

#### In-Market Drugs

- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

#### Late-Stage Pipeline Drugs

- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

#### Competitive Landscape

The competitive landscape of the bacterial vaginosis market has been studied in the report with the detailed profiles of the key players operating in the market.

- AbbVie
- Pfizer
- Lupin
- Dare Bioscience
- Mission Pharmacal
- Osel Inc
- Toltec Pharmaceuticals

Buy Bacterial Vaginosis Epidemiology Report -  
<https://www.imarcgroup.com/checkout?id=7366&method=809>

## 7 Major Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Elena Anderson

IMARC Services Private Limited

+1 631-791-1145

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/823273189>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.